Cardiogen
Evidence: DCardiovascular / Vascular
Evidence Snapshot
What this grade covers
A for canonical sequence identity; C/D for selected laboratory and animal findings (myocardial explant, protein-expression, and tumor-model studies); E for human efficacy, cardiac repair, treatment or prevention of cardiovascular disease, cancer safety, approval, or dosing.
Regulatory Context
No FDA-approved Cardiogen product or verified human clinical development program was identified.
Research Takeaway
Cardiogen in this package refers to the synthetic tetrapeptide Ala-Glu-Asp-Arg (AEDR), not CardioGen-82, natriuretic peptides, unspecified cardiac extracts, or other Khavinson-family peptides.
Evidence boundary: Similar cardiovascular naming does not establish molecular identity.
See all 6 evidence claims →Quick Summary
Cardiogen is a synthetic tetrapeptide commonly identified as Ala-Glu-Asp-Arg (AEDR). The direct literature located is preclinical, including rat myocardial tissue culture, biochemical assays, and a rat tumor model; no controlled human administration study was verified.
Mechanism & Research Overview
The limited literature proposes effects on cell proliferation, apoptosis-related markers, and peptide–DNA interactions. These hypotheses are preclinical and have not been validated as a human cardiovascular mechanism.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Cardiogen in this package refers to the synthetic tetrapeptide Ala-Glu-Asp-Arg (AEDR), not CardioGen-82, natriuretic peptides, unspecified cardiac extracts, or other Khavinson-family peptides.
Does not establish
Evidence boundary: Similar cardiovascular naming does not establish molecular identity.
Sources: AEDR and Cytoskeletal/Nuclear Matrix Protein Expression
Supported
Cardiogen increased proliferative activity in myocardial tissue cultures derived from young and old rats in an ex-vivo experimental model.
Does not establish
Evidence boundary: Tissue-culture proliferation is not evidence that Cardiogen repairs human myocardium or improves cardiovascular outcomes.
Supported
AEDR has been reported to alter expression of cytoskeletal and nuclear-matrix proteins in cultured human fibroblasts, supporting biological activity at the cellular level.
Does not establish
Evidence boundary: Cultured fibroblast findings do not establish organ-specific cardiac benefit in humans.
Sources: AEDR and Cytoskeletal/Nuclear Matrix Protein Expression
Supported
Cardiogen has also been studied in a rat M-1 sarcoma model, where tumor growth and apoptosis-related effects were reported, showing that its biology is not limited to benign cardiac-tissue models.
Does not establish
Evidence boundary: The tumor-model result should not be reframed as evidence that Cardiogen treats cancer, nor does it by itself establish human carcinogenic safety.
Supported
The verified Cardiogen evidence base is dominated by cell, tissue-culture, and animal studies; this package does not identify controlled human trials demonstrating improved heart function, myocardial repair, exercise capacity, or cardiovascular-event reduction.
Does not establish
Evidence boundary: Vendor or bioregulator-program claims cannot substitute for direct controlled human Cardiogen trials.
Sources: AEDR and Cytoskeletal/Nuclear Matrix Protein Expression
Supported
Cardiogen should remain presented as an experimental bioregulatory peptide rather than an established cardiovascular therapy.
Does not establish
Evidence boundary: Scientific publication of mechanistic experiments does not establish drug approval or clinical effectiveness.
Sources: AEDR and Cytoskeletal/Nuclear Matrix Protein Expression
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
No verified human clinical safety or efficacy data were located.Safety Consideration
The small preclinical literature is largely from a single research lineage and includes non-cardiac models.Safety Consideration
Commercial descriptions frequently overstate cardiac repair, mitochondrial, or endothelial claims beyond the primary evidence.Safety Consideration
Product identity and formulation must be analytically confirmed.Safety Consideration
Important uncertainties include: p53 modulation and effects on apoptosis or genomic surveillance; context-dependent stimulation of proliferation; tumor-related and angiogenic effects; unknown receptor or molecular target; unknown cardiac electrophysiology and arrhythmia risk; unknown blood-pressure, vascular, renal, hepatic, neurologic, reproductive, pregnancy, and developmental effects; uncertain pharmacokinetics and tissue distribution; peptide aggregation, impurities, immunogenicity, sterility, and endotoxin risk; product confusion with CardioGen-82 or unrelated cardiac agents; and lack of long-term or repeated-course human data.
Research Areas Being Studied
Research areas discussed on this page reflect the Cardiovascular / Vascular category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| AEDR and Cytoskeletal/Nuclear Matrix Protein Expression | A laboratory study of AEDR/Cardiogen reported altered expression of cytoskeletal and nuclear-matrix proteins. These molecular findings do not establish organ specificity, clinical target engagement, or therapeutic benefit. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| FDA 503A Bulk Drug Substances Categories, Updated May 14, 2026 | 2026 | Cardiogen, Cortagen, Pinealon, and Vesugen were not identified in FDA's current 503A nominated bulk-drug-substance category document, updated May 14, 2026. Absence from that document is not approval, a safety determination, or authorization to compound. | |||
| ClinicalTrials.gov Search Portal | No modern registered interventional development program for Cardiogen, Cortagen, Pinealon, or Vesugen was identified in the reviewed ClinicalTrials.gov searches. | ||||
| Peptide Substance Restoring Myocardium Function (US7662789B2) | A U.S. patent describes AEDR/Cardiogen as a peptide substance related to myocardial function. Patents are intellectual-property documents, not clinical validation of safety or efficacy, and are retained here for identity/history context only. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Peptide regulation of gene expression: a systematic review | 2021 | Systematic review of short-peptide gene-expression studies | The review summarizes proposed DNA and gene-expression effects of short peptides, including organ-labeled bioregulators. | Secondary source dominated by one research program; independent validation remains limited. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-30.
Follow research updates for Cardiogen
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.